BRAFV600E and Microenvironment in Thyroid Cancer: A Functional Link to Drive Cancer Progression
Papillary thyroid cancer (PTC) rates continue to increase in the United States and Europe,
and, although most patients do well, some recur and die of their disease. Patients with PTC …
and, although most patients do well, some recur and die of their disease. Patients with PTC …
[HTML][HTML] Preclinical models of follicular cell-derived thyroid cancer: an overview from cancer cell lines to mouse models
MJ Jeon, BR Haugen - Endocrinology and Metabolism, 2022 - synapse.koreamed.org
The overall prognosis of thyroid cancer is excellent, but some patients have grossly invasive
disease and distant metastases with limited responses to systemic therapies. Thus, relevant …
disease and distant metastases with limited responses to systemic therapies. Thus, relevant …
B-RafV600E and thrombospondin-1 promote thyroid cancer progression
C Nucera, A Porrello, ZA Antonello… - Proceedings of the …, 2010 - National Acad Sciences
Although B-RafV600E is the most common somatic mutation in papillary thyroid carcinoma
(PTC), how it induces tumor aggressiveness is not fully understood. Using gene set …
(PTC), how it induces tumor aggressiveness is not fully understood. Using gene set …
[HTML][HTML] Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of …
E Brauner, V Gunda, PV Borre, D Zurakowski, YS Kim… - Oncotarget, 2016 - ncbi.nlm.nih.gov
The interaction of programmed cell death-1 and its ligand is widely studied in cancer.
Monoclonal antibodies blocking these molecules have had great success but little is known …
Monoclonal antibodies blocking these molecules have had great success but little is known …
Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer
JA Morrison, LA Pike, SB Sams, V Sharma, Q Zhou… - Molecular cancer, 2014 - Springer
Background Thyroid cancer is the most common endocrine malignancy, and many patients
with metastatic differentiated thyroid cancer (DTC), poorly differentiated thyroid cancer …
with metastatic differentiated thyroid cancer (DTC), poorly differentiated thyroid cancer …
Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer
Anaplastic thyroid cancer (ATC), one of the most aggressive solid tumors, is characterized
by rapid tumor growth and severe metastasis to other organs. Owing to the lack of effective …
by rapid tumor growth and severe metastasis to other organs. Owing to the lack of effective …
Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti‐invasive Activity in Preclinical Models of Human Thyroid Cancer
Abstract Purpose. B‐RafV600E may play a role in the progression from papillary thyroid
cancer to anaplastic thyroid cancer (ATC). We tested the effects of a highly selective B …
cancer to anaplastic thyroid cancer (ATC). We tested the effects of a highly selective B …
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model
MK Gule, Y Chen, D Sano, MJ Frederick, G Zhou… - Clinical Cancer …, 2011 - AACR
Purpose: Anaplastic thyroid carcinoma (ATC) is one of the most lethal human cancers with a
median survival of 6 months. The inhibition of epidermal growth factor receptor (EGFR) …
median survival of 6 months. The inhibition of epidermal growth factor receptor (EGFR) …
Cancer stem-like cells and thyroid cancer
Z Guo, H Hardin, RV Lloyd - Endocrine-Related Cancer, 2014 - erc.bioscientifica.com
Thyroid cancer is one of the most rapidly increasing malignancies. The reasons for this
increase is not completely known, but increases in the diagnosis of papillary thyroid …
increase is not completely known, but increases in the diagnosis of papillary thyroid …
AHNAK2 promotes thyroid carcinoma progression by activating the NF-κB pathway
R Ye, D Liu, H Guan, NJ AiErken, Z Fang, Y Shi… - Life sciences, 2021 - Elsevier
Thyroid carcinoma metastasis is the main reason for treatment failure; therefore,
understanding the regulatory mechanisms of thyroid carcinoma metastasis is critical to treat …
understanding the regulatory mechanisms of thyroid carcinoma metastasis is critical to treat …